Skip to content
Screener

Haemonetics HAE PP&E (Net)

PP&E (Net) at other companies

Abbott logo
AbbottABT
$12.81B+12.4%
TFX
TeleflexTFX
$475.64M-13.4%
Boston Scientific logo
Boston ScientificBSX
$4.06B+19.9%
Medtronic logo
MedtronicMDT
$7.42B+8.5%
LivaNova logo
LivaNovaLIVN
$273.34M+39.9%
InfuSystem Holdings logo
InfuSystem HoldingsINFU
$3.22M-18.0%

Segments

By geography

See full
Europe$32.29M+33.6%
Rest of Asia$30.01M+0.6%
Other$17.59M-1.2%

By segment

See full
Apheresis$244.09M
MedSurg$59.69M

Other financials

Income statement

See full
Revenue$339.4M+5.6%
Gross profit$202.8M+5.5%
Operating income$57.5M+6.7%
Net income$33.0M-3.0%
EPS (diluted)$0.72+2.9%

Balance sheet

See full
Cash & equivalents$223.4M-23.7%
Total debt$1.2B-4.1%
Total equity$837.1M-5.1%
Total assets$2.4B-3.9%

Cash flow

See full
Operating cash flow$52.3M+201%
CapEx$7.9M+111%
Free cash flow$44.4M+226%

Valuation

See full
Market cap$4B+58.1%
Enterprise value$4.95B+43.0%
P/E26.6×-10.9×
P/S+1.1×

Profitability

See full
Gross margin59%+2.1pp
Operating margin19%+5.9pp
Net margin13.3%+3.8pp
FCF margin21.5%+7.5pp

Returns & leverage

See full
Return on equity19.3%+5.2pp
Debt / equity1.4×0.0×
Current ratio3.1×+1.4×

Where this comes from

Reported directly by Haemonetics in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The source filing: Haemonetics’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 6:09 AM EDT
Fiscal quarter
Q1 FY2027
Calendar quarter
Q2 2026
Accession
0000313143-26-000120
Line itemJune 27, 2026March 28, 2026
Inventories, net306,739306,370
Prepaid expenses and other current assets64,63866,214
Total current assets810,832834,879
Property, plant and equipment, net303,778305,761
Intangible assets, less accumulated amortization of $374,828 as of June 27, 2026 and $363,763 as of March 28, 2026434,512447,655
Goodwill656,884656,368
Deferred tax asset9,4349,521
Other long-term assets149,960141,741

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Haemonetics's PP&E (net)?
Haemonetics (HAE) reported PP&E (net) of $303.78M in Q2 2026.
How has Haemonetics's PP&E (net) changed year-over-year?
Haemonetics's PP&E (net) increased by 5.9% year-over-year, from $286.87M to $303.78M.
What is the long-term trend for Haemonetics's PP&E (net)?
Over 5 years (2021 to 2026), Haemonetics's PP&E (net) has grown at a 7.0% compound annual growth rate (CAGR), from $217.56M to $305.76M.
What does PP&E (net) mean?
Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.

Ask your AI about Haemonetics's pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude